Cytiva formed through the divestiture of the GE Healthcare Biopharma business to Danaher Corporation in 2020. Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Cytiva have a rich heritage tracing back hundreds of years. Their customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva supplies the tools and services they need to work better, faster and safer, leading to better patient outcomes.

Scientists around the world make new discoveries and breakthroughs every day leading to improved understanding for protein science and transforming peoples’ lives.

Their well-established brands; ÄKTA™, Biacore™, Amersham™, Whatman™ and many more, support scientists to advance isolation and cloning, cell culture, purification and analysis.

Cytiva (as GEHC) entered in to a partnership with SBC to allow occupiers based on the campus to access instruments and GE expertise.